KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Assets: 2020-2024

Historic Current Assets for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $751.4 million.

  • AbCellera Biologics' Current Assets fell 6.43% to $695.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $695.1 million, marking a year-over-year decrease of 6.43%. This contributed to the annual value of $751.4 million for FY2024, which is 13.83% down from last year.
  • AbCellera Biologics' Current Assets amounted to $751.4 million in FY2024, which was down 13.83% from $872.0 million recorded in FY2023.
  • AbCellera Biologics' Current Assets' 5-year high stood at $1.0 billion during FY2022, with a 5-year trough of $751.4 million in FY2024.
  • Moreover, its 3-year median value for Current Assets was $872.0 million (2023), whereas its average is $882.9 million.
  • Its Current Assets has fluctuated over the past 5 years, first grew by 14.32% in 2021, then decreased by 14.97% in 2023.
  • AbCellera Biologics' Current Assets (Yearly) stood at $813.3 million in 2020, then grew by 14.32% to $929.8 million in 2021, then climbed by 10.29% to $1.0 billion in 2022, then decreased by 14.97% to $872.0 million in 2023, then decreased by 13.83% to $751.4 million in 2024.